18F-fluorodeoxyglucose PET in ovarian carcinoma: Methodology and preliminary results;18F-fluordeoxyglukose PET beim ovarialkarzinom: Methodik und erste Ergebnisse

NuklearMedizin

Volumn 36, Issue 7, 1997, Pages 228-233

  Zimny, M ^a,b   Schroder W ^a   Wolters, S ^a   Cremerius, U ^a   Rath, W ^a   Bull U ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

Author keywords

18FDG; Ovarian cancer; Peritoneal carcinomatosis; Positron emission tomography

Indexed keywords

FLUORODEOXYGLUCOSE F 18; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; OVARY CARCINOMA; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CYSTADENOCARCINOMA; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; RECURRENT DISEASE; REPRODUCIBILITY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY; TUMOR RECURRENCE;

ADULT; AGED; CYSTADENOCARCINOMA; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; RADIOPHARMACEUTICALS; RECURRENCE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030609054     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0038-1629838     Document Type: Article

References (17)

1. Bares R, Dohmen BM, Cremerius U, Faß J, Teusch M, Bull U. Ergebnisse der Positronenemissionstomographie mit Fluor-18-markierter Fluordeoxyglucose bei Differential-diagnose und Staging des Pankreaskarzinoms. Radiologe 1996; 36: 435-40.
2. Barzen G, Cordes M, Langer M, Friedmann W, Mayr AC, Felix R. Wertigkeit der Radioimmunszintigraphie im Vergleich zur Computertomographie in der Diagnostik und Verlaufskontrolle des primären Ovarialkarzinoms. Fortschr Rontgenstr 1990; 153: 85-91.
3. Bischof-Delaloye A, Wahl R. How high a level of FDG abdominal activity is considered normal ? (abstract) J Nucl Med 1995; 36: 106p.
4. Braggs DG, Hricak H. Imaging in gynecologic malignancies. Cancer 1993; 71: 1648-51.
5. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecologic oncology 1994; 53: 331-8.
6. Hoffman EJ, Sung-Cheng H, Phelps ME. Quantitation in Positron emission computed tomography: 1. Effect of object size. J Comput Assist Tomogr 1979; 3: 299-308.
7. Hubner KF, McDonald TW, Niethammer JG, Smith GT, Gould HR, Buonocore E. Assessment of primary and metastatic ovarian cancer by positron emission tomographie (PET) using 2-[18-F]deoxyglucose (2-[18F]FDG). Gynecologic oncology 1993; 51: 192-204.
8. Karlan BY, Hoh C, Tse N, Futoran R, Hawkins R, Glaspy J. Whole-body positron emission tomography with (fluorine-18)-2-deoxyglucose can detect metastatic carcinoma of the fallopian tube. Gynecologic oncology 1993; 49: 383-8.
9. Krag ND. Clinical Utility of Immunscintigraphy in Managing Ovarian Cancer. J Nucl Med 1993; 34: 545-8.
10. Method MW, Serafim AN, Averette HE, Rodriguez M, Penalver MA, Sevin BU. The role of Radioimmunoscintigraphy and Computed Tomography Scan prior to Reassessment Laparotomy of Patients with Ovarian Carcinoma. Cancer 1996; 77: 2286-93.
11. Reske SN, Bares R, Bull U, Guhlmann A, Moser E, Wannenmacher MF. Klinische Wertigkeit der Positronen-Emissions-Tomographie (PET) bei onkologischen Fragestellungen: Ergebnisse einer interdisziplinären Konsensuskonferenz. Nuklearmedizin 1996; 35: 42-52.
12. Romer W, Avril N, Dose J, Ziegler S, Kuhn W, Herz M, Janicke F, Schwaiger M. Metabolische Charakterisierung von Ovarialtumoren mit der Positronen-Emissions-Tomographie und F-18-Fluordeoxyglukose. Fortschr Röntgenstr 1997; 166: 62-8.
13. Shepp LA, Vardi Y. Maximum likelihood reconstruction for positron emission tomography. IEEE Trans Med Imaging 1982; 2: 113-22.
14. Soper JT. Malignancies of the Ovary and Fallopian Tube. In: Multimodality Therapy in Gynecologic Oncology. Sevin BU. ed. Stuttgart, New York: Thieme 1996; 135-90.
15. Tahara T, Ichiya Y, Kubawara Y, Otsuka M, Miyake Y, Gunasekera R, Masuda K. High F-18 fluorodeoxyglucose uptake in abdominal abscesses. A PET-study. J Comput Assist Tomogr 1989; 13: 829-31.
16. Wahl RL, Hutchins GD, Buchsbaum DJ, Liebert M, Grossmann HB, Fisher S. 18F-2-Deoxy-2-Fluoro-D-Glucose Uptake into Human Tumor Xenografts. Cancer 1991; 67: 1544-50.
17. Yancik R. Ovarian cancer: age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer 1993; 71: 517-23.